At a Glance
Delphi Ventures is a San Francisco-based venture capital firm that focuses on early-stage investments across healthcare, fintech, and emerging technology sectors. The firm takes a founder-centric approach, emphasizing strong founder-market fit as a key investment criterion when evaluating opportunities from pre-seed through Series B stages.
The firm has built a notable portfolio spanning multiple high-growth sectors. In healthcare, Delphi Ventures backed Synthego, a genome engineering company that provides CRISPR tools and services, and Guardant Health, which became a leading liquid biopsy company and successful public offering. In quantum computing, they invested in Rigetti Computing, one of the pioneering companies in quantum cloud services and processors.
Delphi Ventures' investment strategy focuses on identifying companies with strong technological differentiation and large addressable markets. The firm's partners, including Deepa Pakianathan, bring operational experience and industry connections that help portfolio companies scale effectively. Their approach emphasizes supporting founders through multiple stages of growth, often participating in follow-on rounds as companies mature.
“Focuses on early-stage investments in healthcare, fintech, and technology companies with strong founder-market fit.”
Delphi Ventures primarily invests at the Pre-Seed, Seed, Series A, Series B+ stages. This means they focus on companies that are at the earliest idea or prototype phase.
Delphi Ventures is headquartered in San Francisco, CA. Many of their portfolio companies are also based in this region, though they invest across geographies.
Delphi Ventures focuses on investments in Aerospace & Defense, Digital Health, Other, Consumer, Fintech. Their portfolio reflects deep expertise and networks within these sectors.
Delphi Ventures's typical investment check size ranges from $50K to $5M. Actual amounts may vary based on the stage, sector, and specific opportunity.
